2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1067

History of Thrombocytopenia Is Associated with Lower Prevalence of Thrombotic Events in Systemic Lupus Erythematosus Patients with Antiphospholipid Antibodies
Abstract Number: 805

HLA Class II Functional Motifs Associated with Severe Systemic Sclerosis (SSc) and Sclerotic Graft Versus Host Disease (sclGVHD): The Shared Epitopes of Fibrosis
Abstract Number: 3166

HLA-B27 and Ankylosing Spondylitis Have Shared Effects on the Gut Microbiome
Abstract Number: 3165

HLA-B27 Expression Is Accompanied By a Profoundly Altered IgA Response to the Intestinal Microbiota and Microbial Translocation to the Joint
Abstract Number: 2932

HLA-DR3 Restricted Response to Lupus-Related Auto-Antigen Smd: Autoreactive T Cells Are Inherent in Normal Immune Repertoires
Abstract Number: 2933

HLA-DR3 Restricted T Cell Response to Smd and Ro60 Reveals Multiple Cross-Reactive Intra- and Inter-Molecular T Cell Epitopes: Unique Antigenic Structures of Lupus-Related Auto-Antigens and the Basis for B Cell Epitope Spreading
Abstract Number: 2742

How Are Enthesitis, Dactylitis and Nail Involvement Measured and Reported in Recent Clinical Trials of Psoriatic Arthritis (PsA)? a Systematic Literature Review
Abstract Number: 1959

How Do Bone Marrow Lesions Cause Osteoarthritis Pain? a Structural and Functional Tissue-Based Study
Abstract Number: 2682

How Does Primary Sjogren Syndrome Present in Biopsy-Proven Patients without Circulating Ro/La Autoantibodies? Characteristics at Diagnosis of 2073 Patients from the SjöGren Big Data Project
Abstract Number: 263

How Does Sarcoidosis Present in Spain? Characteristics at Diagnosis of 979 Patients from the Sarcogeas-SEMI Registry
Abstract Number: 38

How Does Thiol/Disulphide Homeostasis Change in Fibromyalgia Patients?
Abstract Number: 1162

How Ehealth Technologies Are Changing the Office Visit: Perspectives from Healthcare Professionals in Rheumatology
Abstract Number: 1519

How Much, and When, Does Autoimmune Thyroid Disease Increase the Risk of RA, and Does RA-Onset Impact the Risk of Autoimmune Thyroid Disease?
Abstract Number: 2469

How Rheumatoid Arthritis Patients and Rheumatologists Communicate during Clinic Visits When a New DMARD Is Prescribed
Abstract Number: 930

How to Implement Cardiovascular Disease Risk Assessment for Patients with Inflammatory Joint Diseases in Daily Rheumatology Practice: An Overview of a Nationwide Norwegian Project

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].